GLP-1 receptor agonists reduced all-cause mortality by 52% in heart failure patients already receiving guideline-directed medical therapy, according to analysis of 3,036 patients across multiple medical centers. The drugs cut death rates from 23.8% to 12.8% over two years, while also reducing major cardiovascular events by 36% and critical care utilization by 45%. This represents one of the most substantial mortality benefits reported for any heart failure intervention in recent years. The findings suggest GLP-1 drugs could become a transformative fifth pillar of heart failure treatment, complementing existing therapies through novel metabolic mechanisms. These medications, originally developed for diabetes and obesity, appear to offer cardioprotective effects that extend beyond their metabolic benefits. However, this remains a preprint awaiting peer review, and the retrospective design cannot establish causation despite propensity matching. The magnitude of benefit—an 11% absolute risk reduction in mortality—would rival or exceed established heart failure medications if confirmed in randomized trials. This could fundamentally reshape heart failure management for millions of patients worldwide.